Altimmune Inc
NASDAQ:ALT

Watchlist Manager
Altimmune Inc Logo
Altimmune Inc
NASDAQ:ALT
Watchlist
Price: 3.982 USD -21.15%
Market Cap: 415.1m USD

Operating Margin
Altimmune Inc

-452 310%
Current
-146 385.5%
Average
-4.1%
Industry

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-452 310%
=
Operating Profit
-90.5m
/
Revenue
20k

Operating Margin Across Competitors

Country Company Market Cap Operating
Margin
US
Altimmune Inc
NASDAQ:ALT
380.7m USD
-452 310%
FR
Pharnext SCA
OTC:PNEXF
6T USD
-17 527%
US
Abbvie Inc
NYSE:ABBV
395B USD
33%
US
Amgen Inc
NASDAQ:AMGN
176.5B USD
34%
US
Gilead Sciences Inc
NASDAQ:GILD
151.9B USD
39%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
113.3B USD
39%
US
Epizyme Inc
F:EPE
94.1B EUR
-370%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
79.6B USD
28%
AU
CSL Ltd
ASX:CSL
84.8B AUD
26%
NL
argenx SE
XBRU:ARGX
44.4B EUR
22%
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
52.8B USD
8%
No Stocks Found

Altimmune Inc
Glance View

Market Cap
380.7m USD
Industry
Biotechnology

Altimmune, Inc. is a clinical stage biopharmaceutical company, which focuses on peptide-based therapeutics for obesity and liver diseases. The company is headquartered in Gaithersburg, Maryland and currently employs 47 full-time employees. The company went IPO on 2005-10-06. The Company’s lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and non-alcoholic steatohepatitis (NASH). The company is also developing HepTcell, an immunotherapeutic agent designed to achieve a functional cure for chronic hepatitis B. The firm has initiated a Phase II clinical trial of HepTcell and are in Phase II and Phase I clinical development with pemvidutide for multiple indications. The company is conducting its Phase II clinical trial of HepTcell in the United States, United Kingdom, Canada, Germany and Spain, and conducting Its pemvidutide Phase I clinical trial in Australia. Its wholly owned subsidiaries include Altimmune, LLC, Altimmune UK, Limited, Spitfire Pharma, LLC and Altimmune AU Pty, Limited.

ALT Intrinsic Value
5.78 USD
Undervaluation 31%
Intrinsic Value
Price
What is Operating Margin?

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-452 310%
=
Operating Profit
-90.5m
/
Revenue
20k
What is the Operating Margin of Altimmune Inc?

Based on Altimmune Inc's most recent financial statements, the company has Operating Margin of -452 310%.

Back to Top